|
Links
to other pages
|
|
Full
text (leads off this site)
|
 |
| The Consensus Statement was developed at the National Institutes of Health (NIH) Development Conference, December 11-13, 1991 (Volume 9, Number 4). The conference was convened "to evaluate available scientific information and resolve safety and efficacy issues related to a biomedical technology. The resultant NIH consensus statements are intended to advance understanding of the technology or issue in question and to be useful to health professionals and the public."Copies of the statement and bibliographies, as prepared by the National Library of Medicine are available from the Office of Medical Applications of Research, National Institutes of Health, Federal Building, Room 618, Bethesda, MD 20892. The bibliographic reference is: Acoustic Neuroma. NIH Consensus Statement 1991 Dec 11-13; 9(4):1-24. |
| The
National Institutes of Health Consensus Development Conference on Acoustic
Neuroma brought together neurosurgeons, radiosurgeons, otologists, neurologists,
audiologists, otolaryngologists, and other health care professionals as
well as the public to reach agreement (1) on defining the clinical types
of acoustic neuroma, (2) on which procedures are useful for screening
and diagnosis, (3) on the options available for managing the disorder
as well as the complications of treatment, and (4) on the key clinical
and biological areas for future research. Following 2 days of presentations
by experts and discussion by the audience, a consensus panel weighed the
evidence and prepared their consensus statement. Among their findings, the panel concluded that (1) the term vestibular schwannoma is preferred over acoustic neuroma as these tumors are composed of Schwann cells and typically involve the vestibular rather than the acoustic division of the 8th cranial nerve; (2) treatment for vestibular schwannoma must be individualized and requires an experienced, well-integrated, multidisciplinary team approach; (3) surgery remains the treatment of choice, but research is needed on the relative benefits and risks of all management options, including pharmaceutical and other alternative medical treatments such as tumor suppressing agents; (4) routine intraoperative monitoring of facial nerve should be included in surgical therapy for vestibular schwannoma; (5) neurofibromatosis 2 (NF2) should be carefully considered in all patients newly diagnosed with vestibular schwannoma, and when found, genetic evaluation and counseling should be provided for all relevant family members; and (6) a registry of all patients with vestibular schwannoma, whether undergoing observation or active management, should be established. |
| The full text of the Consensus Statement can be found at the following URL: http://text.nlm.nih.gov/nih/cdc/www/87.html. Clicking here takes you off the Seattle Ear Clinic Site, so you might want to bookmark the Seattle Ear Clinic site now. |